You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic Castration Resistant

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • mCRPC
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Jul 20, 2022

Castration-resistant Prostate Cancer, Metastatic Cancer Trial (Cabozantinib, Nivolumab)

Not yet recruiting
  • Castration-resistant Prostate Cancer
  • Metastatic Cancer
  • (no location specified)
Aug 12, 2022

Metastatic Castration Resistant Prostate Cancer (mCRPC) Trial (Pidnarulex, Talazoparib)

Not yet recruiting
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jun 15, 2022

Metastatic Castration-resistant Prostate Cancer Trial in La Jolla (Cirmtuzumab)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • La Jolla, California
    University of California San Diego
May 22, 2022

Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer Trial in Melbourne (Lutetium-177 PSMA-I&T, Radium-223)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Jul 20, 2022

Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Aug 16, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Mexico City (SV-102)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Mexico City, Mexico
    Hospital Diomed
Sep 14, 2022

Metastatic Castration Resistant Prostate Cancer Trial in China (AC176)

Not yet recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Beijing, China
  • +4 more
Jan 4, 2023

Castration-resistant Prostate Cancer Trial in Los Angeles (Apalutamide, Carotuximab)

Not yet recruiting
  • Castration-resistant Prostate Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Sep 6, 2022

Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma Trial in Ann Arbor

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Mar 31, 2022

Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)

Not yet recruiting
  • Prostate Cancer Metastatic
  • (no location specified)
Sep 29, 2022

Metastatic Castration-resistant Prostate Cancer Trial (TmPSMA-02)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TmPSMA-02
  • (no location specified)
Aug 3, 2022

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Seoul ([177Lu]Ludotadipep)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer, mCRPC
  • Seoul, Korea, Republic of
    The Catholic University of Korea, Seoul, St, Mary's Hospital, 22
Dec 8, 2022

Metastatic Castration Resistant Prostate Cancer Trial in London (IMU-935)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • London, United Kingdom
    Institute of Cancer Research
Feb 1, 2022

Metastatic Castration-resistant Prostate Cancer Trial (Darolutamide, Docetaxel or cabazitaxel)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Feb 28, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Enfortumab vedotin)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Enfortumab vedotin
  • Salt Lake City, Utah
    Huntsman Cancer Institute
Feb 3, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.1 GBq (30 mCi) of 177Lu-P17-087
  • 1.1 GBq (30 mCi) of 177Lu-P17-088
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 30, 2022

Prostatic Tumors, Castration-Resistant Trial in New York (TVB-2640, Enzalutamide)

Not yet recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Feb 23, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 6, 2022

Metastatic Castration-resistant Prostate Cancer Trial in China (TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TQB3823 tablets
  • +2 more
  • Chongqing, Chongqing, China
  • +4 more
Jun 1, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Nivolumab)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Apr 21, 2022

Called DEAR, to Learn More About Treatment With Darolutamide,

Active, not recruiting
  • Non-metastatic Castration-resistant Prostate Cancer
  • Darolutamide (Nubeqa, BAY1841788)
  • +2 more
  • Whippany, New Jersey
    Bayer
Jul 29, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Nov 10, 2022

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate Cancer
  • FOR46
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 1, 2022

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial in Shanghai (Abiraterone Acetate Tablets (I), ZYTIGA®)

Completed
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 16, 2022